Free Trial
NASDAQ:BRTX

Biorestorative Therapies Q4 2023 Earnings Report

Biorestorative Therapies logo
$1.45 0.00 (-0.07%)
As of 09/19/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Biorestorative Therapies EPS Results

Actual EPS
-$0.57
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biorestorative Therapies Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
$0.03 million
Beat/Miss
Missed by -$10.00 thousand
YoY Revenue Growth
N/A

Biorestorative Therapies Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, April 1, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Biorestorative Therapies' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Biorestorative Therapies Earnings Headlines

If You Keep Cash In A U.S. Bank Account… Read This NOW
The Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of customer deposits as Americans rush into a new form of money… That’s just been authorized under President Trump’s highly controversial new law, S.1582.tc pixel
Earnings Outlook For BioRestorative Therapies
See More Biorestorative Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biorestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biorestorative Therapies and other key companies, straight to your email.

About Biorestorative Therapies

Biorestorative Therapies (NASDAQ:BRTX) Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy. Biorestorative Therapies’ candidate has completed early-stage clinical evaluation and is advancing through planned trials to assess safety and efficacy in reducing the duration and severity of oral mucositis. Preclinical studies have also been conducted to explore additional indications, including inflammatory and degenerative conditions.

Headquartered in Malvern, Pennsylvania, Biorestorative Therapies manages its research, manufacturing and clinical development activities in the United States. The company works with clinical research organizations and academic centers to support its ongoing trials and maintains a leadership team with experience spanning cell therapy, clinical development and regulatory affairs. Biorestorative Therapies continues to pursue partnerships to expand its pipeline and accelerate the path to potential regulatory approval.

View Biorestorative Therapies Profile

More Earnings Resources from MarketBeat